FREE BODY SURFACE AREA CALCULATOR : BSA IN M² (5 FORMULAS)

BSA is the total external surface area of the human body, expressed in square metres (m²). It matters because BSA scales more accurately with lean body mass and metabolic organ function than body weight — making it the preferred basis for chemotherapy dosing, cardiac index calculation, eGFR normalisation (1.73 m² reference), and clinical nutrition calculations. Unlike BMI which measures a ratio, BSA measures actual physical size. The average adult BSA is approximately 1.60–1.90 m² depending on sex, height, and weight.

Normal adult BSA ranges: Males — 1.60 to 2.30 m², average 1.90 m². Females — 1.40 to 1.95 m², average 1.60 m². The clinical reference constant of 1.73 m² was the average BSA of a 1950s US reference adult. Athletes and bodybuilders typically have BSA of 2.00–2.60 m² due to greater lean muscle mass. Children’s BSA ranges from ~0.25 m² at birth to adult values (~1.4–1.7 m²) by mid-adolescence. BSA above 2.50 m² occurs in very tall or very muscular individuals only.

For most adults with a BMI of 18.5–35, all five equations agree within ±5% and the choice is often institutional preference. Mosteller is the most widely used clinically due to its simplicity. Haycock is the most accurate for lean individuals, children, and low body fat athletes. Du Bois remains essential because it is the formula specified in many older drug monographs. Fujimoto is recommended for East Asian populations. Divergence between formulas increases meaningfully in extreme obesity (BMI >40) or very low body weight (BMI <16) — in those populations the Haycock or a 3D scan-based measurement is preferable.

The 1.73 m² reference was established in the 1920s–1950s as the average BSA of a 70 kg standard US adult. It was adopted as the normalisation denominator for GFR (kidney filtration rate) because it allows kidney function to be compared across all individuals regardless of body size. This value persists as a conventional clinical constant rather than a true current population average — modern adults are considerably larger (average male BSA ~1.90 m²). The 1.73 m² reference is also used for cardiac index, paediatric drug dosing scales, and metabolic rate normalisation.

BMI (Body Mass Index) = Weight(kg) ÷ Height(m)². It is a dimensionless ratio that estimates whether weight is appropriate for height — used for population-level obesity screening. It does not measure actual body size or distinguish muscle from fat. BSA measures the actual physical surface area of your body in m² — it scales with real body dimensions and is used for drug dosing, cardiac index, and eGFR normalisation. A bodybuilder and an obese individual can have the same BMI but very different BSA and body composition. BSA is far more relevant in clinical pharmacology; BMI is more relevant in epidemiological risk screening.

Not accurately using standard validated equations — all five major BSA formulas (Mosteller, Du Bois, Haycock, Gehan-George, Fujimoto) require both height and weight. Height is essential because BSA scales with the total body surface, which is determined by both the vertical dimension (height) and horizontal dimensions (related to weight). Some simplified emergency estimation methods use only weight with fixed population height assumptions, but these introduce significant errors of ±10–20%. For any clinically important BSA calculation (particularly chemotherapy dosing), both measured height and weight are mandatory.

Yes — BSA changes with any significant change in body weight or, in children and adolescents, with height growth. For adults with stable weight, BSA changes minimally over months. When to recalculate: Whenever body weight changes by ≥5 kg (≥10 lbs); for children — before every chemotherapy cycle as they are growing; for athletes — quarterly or at the start of each competitive season; at significant body recomposition milestones (cutting, bulking, significant weight loss). In oncology, BSA is remeasured at each chemotherapy cycle to ensure dosing accuracy — particularly in patients losing weight due to disease or treatment.

True direct BSA measurement is complex and impractical in clinical settings. Historical methods included coating the body surface with paper or paint and measuring the area. Modern direct measurement uses 3D whole-body surface scanning — structured light or photogrammetry scanners that create a 3D point cloud of the body surface, from which precise surface area is calculated. These systems are used in research, military applications, and some advanced burn units. They consistently show that Du Bois-derived equations underestimate true BSA by 3–5% in modern Western adults who are larger than the original 1916 population. For practical clinical purposes, the formula-based equations remain the standard.

The Mosteller formula (1987): BSA = √(Height(cm) × Weight(kg) / 3600). It is the most widely used BSA equation in modern clinical practice for three reasons: (1) it is mathematically simple and can be calculated on a basic calculator or memorised; (2) it produces results within 2–3% of more complex equations across most adult body sizes; (3) it is specified in the majority of current oncology dosing protocols and clinical pharmacokinetic studies. The Imperial version is: BSA = √(Height(in) × Weight(lbs) / 3131). A 2010 comparative study of 3,500 patients found Mosteller and Du Bois agreed within 2% in over 90% of adult patients — validating Mosteller as an appropriate simplification.

The Du Bois formula (1916): BSA = 0.007184 × Weight(kg)^0.425 × Height(cm)^0.725. Developed by Delafield Du Bois and Eugene Floyd Du Bois from only 9 subjects, it is remarkably the most cited BSA formula in all of medical literature with over a century of clinical validation. It remains used because: (1) many older drug monographs and clinical references explicitly specify Du Bois BSA; (2) it performs well in the normal BMI range; (3) historical dosing data from decades of clinical trials was derived using this formula. Its main limitation is underestimating BSA in obese patients (BMI >35) — where it produces results 5–8% lower than 3D scanning. It slightly overestimates BSA in very short individuals.

The Haycock formula (1978): BSA = 0.024265 × Height(cm)^0.3964 × Weight(kg)^0.5378. It should be prioritised when: (1) calculating BSA in children of any age — it was derived from a dataset spanning neonates to adults, making it the most age-diverse validation; (2) calculating BSA in lean adults with low body fat (BMI <22), where other formulas slightly overestimate; (3) paediatric oncology and haematology chemotherapy dosing, where it is the de facto standard. The Haycock formula is particularly recommended in the Journal of Pediatrics and is incorporated into most paediatric pharmacy references. For standard-weight adults, Haycock and Mosteller typically agree within ±2%.

The Gehan-George formula (1970): BSA = 0.0235 × Weight(kg)^0.51456 × Height(cm)^0.42246. Derived from 401 subjects including a diverse range of cancer patients, it remains one of the most commonly cited BSA equations in oncology literature and is specified in a number of chemotherapy protocols particularly in the United States. It tends to produce slightly higher BSA estimates than Mosteller in patients with higher weights — which can be relevant for dose calculations in patients with cancer-related weight gain. Multiple oncology institutions have adopted Gehan-George as their institutional standard, making it important to know which formula your treating oncologist’s protocol specifies.

Each formula was derived from different sample populations of varying size, age, ethnicity, and health status — producing different regression coefficients. At normal BMI (18.5–25), all five formulas typically agree within ±3%, and the clinical difference is negligible. Divergence increases with: (1) Extreme obesity (BMI >40) — Du Bois underestimates, Gehan-George produces the highest values; (2) Very low weight (BMI <16) — Du Bois overestimates slightly; (3) Children — adult-derived formulas systematically overestimate; (4) East Asian populations — Western formulas overestimate compared to Fujimoto. A 2016 PubMed comparative study found the maximum divergence between formulas was 8.3% in morbidly obese patients — representing a clinically meaningful dose difference in chemotherapy.

Your eGFR is expressed per 1.73 m² BSA — it represents the GFR you would have if your BSA were exactly 1.73 m². Your true absolute GFR = reported eGFR × (your BSA ÷ 1.73). Example: BSA of 2.20 m² (typical large male athlete) and reported eGFR of 75 → true absolute GFR = 75 × (2.20 / 1.73) = 97 mL/min — completely normal. Conversely, a petite woman with BSA 1.50 m² and eGFR of 95 has a true absolute GFR of 95 × (1.50 / 1.73) = 82 mL/min. This BSA correction is most clinically relevant for very large or very small individuals, and for drug dosing decisions requiring absolute GFR.

Not directly. A high BSA simply means your kidneys filter more total volume per minute to maintain the same normalised eGFR per 1.73 m². Kidney health is determined by your normalised eGFR and urinary albumin-to-creatinine ratio (ACR) — not absolute GFR. A very tall, muscular athlete may have a reported eGFR of 78 mL/min/1.73m² (Stage G2 borderline) but a true absolute GFR of 100+ mL/min — meaning kidney function is entirely normal. BSA knowledge helps contextualise borderline eGFR results in large-bodied individuals and prevents misdiagnosis of CKD in athletes with physiologically elevated creatinine and large BSA.

Cockcroft-Gault (CG) estimates creatinine clearance (CrCl) in mL/min — not BSA-normalised. eGFR (CKD-EPI, MDRD) estimates GFR in mL/min/1.73 m² — BSA-normalised. CG requires body weight and produces an absolute clearance value that increases with body weight. BSA-normalised eGFR is independent of body size — making it better for CKD staging. For drug dosing: always check whether the drug trial or monograph used CG or CKD-EPI, and use the same equation — the difference matters particularly in extremes of body size. CG consistently overestimates GFR by 10–20% compared to CKD-EPI because tubular creatinine secretion contributes to CrCl but not true GFR.

Chemotherapy drugs are dosed per m² BSA because drug clearance (hepatic metabolism + renal excretion) correlates better with BSA than raw body weight — which includes metabolically variable fat mass. BSA-based dosing reduces inter-patient variability in drug exposure and balances under-dosing (inadequate tumour kill) against over-dosing (severe toxicity). The method has been standard for over 50 years. Common BSA-based doses: paclitaxel 175 mg/m², doxorubicin 60–75 mg/m², cyclophosphamide 600 mg/m². Importantly, a Nature 2002 analysis (Gurney) noted that BSA dosing still leaves 20–30% inter-patient pharmacokinetic variability unaccounted for — which is why therapeutic drug monitoring (TDM) is increasingly used for selected agents.

Yes — BSA-based dosing extends beyond oncology: Carboplatin uses the Calvert formula (dose = AUC × [eGFR + 25]); Immunosuppressants in transplant recipients (basiliximab, rabbit anti-thymocyte globulin); Biologics in paediatrics (rituximab, bevacizumab, trastuzumab); Intravenous immunoglobulin (IVIG) in select protocols; Aminoglycosides in some extended-interval dosing protocols. Cardiac drugs: cardiac index (CI) is calculated by dividing cardiac output by BSA. For most common oral medications, fixed or weight-based dosing is used — BSA-based dosing is predominantly a parenteral (IV) drug approach used when precise dose-exposure titration is critical.

BSA capping means a protocol specifies a maximum BSA value for dose calculation — regardless of the patient’s actual BSA. Common caps: 2.0 m² (most common), 2.2 m², or 2.5 m² depending on the drug. The rationale: (1) Clinical trial populations that established safe doses rarely included patients with BSA >2.0–2.2 m², making higher doses untested; (2) drug clearance does not always scale linearly with BSA at extreme values; (3) manufacturing and economic constraints around very large single doses. The downside of arbitrary capping: larger patients may be systematically underdosed relative to their true metabolic requirement — an ongoing controversy in oncology pharmacology. Always check the specific protocol’s BSA cap — it varies by drug and institution.

Formula: Total dose (mg) = Drug dose per m² (mg/m²) × Patient BSA (m²). Example: Paclitaxel 175 mg/m² in a patient with BSA 1.78 m² → 175 × 1.78 = 311.5 mg. In practice, oncology pharmacists apply dose rounding (to the nearest practical vial size), check for BSA caps, verify organ function (LFTs for hepatic clearance, eGFR for renally cleared drugs), and cross-reference with the specific regimen protocol. Important: Never use a BSA calculator result to independently adjust your own chemotherapy dose. Dose calculation in oncology must always be performed and verified by a qualified oncology pharmacist or clinician using validated institutional systems.

The Calvert formula calculates carboplatin dose based on target drug exposure (AUC) rather than simple BSA: Carboplatin dose (mg) = AUC × (GFR + 25). Where GFR is measured or estimated in mL/min (non-BSA-normalised). This formula combines both eGFR (kidney clearance) and BSA concepts — because carboplatin is almost entirely renally eliminated, its clearance correlates more directly with GFR than with BSA alone. Typical AUC targets: 5–6 mg/mL·min (first-line combination), 4–5 (previously treated). The 25 constant represents non-GFR clearance (tubular secretion + non-renal). KDIGO 2024 recommends using absolute (non-BSA-normalised) GFR × (patient BSA / 1.73) for accurate Calvert carboplatin dosing in patients with non-standard BSA.

Yes — this is a major ongoing clinical debate. In obese patients, actual BSA is elevated due to adipose tissue, which is metabolically less active than lean mass. Dosing to full actual BSA can risk overdosing relative to metabolic capacity. However, the American Society of Clinical Oncology (ASCO) guideline recommends using actual body weight (and thus actual BSA) for chemotherapy dosing in obese patients — because underdosing to lean body weight or ideal body weight has been associated with worse cancer outcomes. For patients with a BMI >40, ASCO recommends using actual weight unless an institutional protocol specifically specifies otherwise — and consulting an oncology pharmacist for all cases at the extremes of BSA.

Cardiac Index (CI) = Cardiac Output (L/min) ÷ BSA (m²). It is the BSA-normalised measure of how much blood the heart pumps per minute — allowing direct comparison between patients of different body sizes. Normal CI: 2.5–4.0 L/min/m². CI below 2.2 L/min/m² = low cardiac output syndrome (cardiogenic shock risk). CI above 4.5 = high output states (fever, sepsis, anaemia, pregnancy, thyrotoxicosis). Athletes typically have resting CI of 3.5–5.0 L/min/m² due to cardiac hypertrophy (athlete’s heart) producing elevated stroke volume. Without BSA normalisation, a 120 kg athlete would always appear to have a higher cardiac output than a 60 kg individual — making comparison impossible. Cardiac index is routinely measured in ICU settings via pulmonary artery catheter, transoesophageal echocardiography, or transpulmonary thermodilution.

Yes — in cardiology, BSA is used to normalise cardiac chamber dimensions and great vessel measurements. Aortic root diameter indexed to BSA (aortic root / BSA) is a critical measurement in aortic disease — an aortic root diameter >2.1 cm/m² BSA is the threshold often used to guide surgical intervention in aortic aneurysm (particularly in Marfan syndrome). Similarly, echocardiographic measurements of left ventricular internal dimensions, wall thickness, and mass are all indexed to BSA to allow comparison across patients of different sizes. This is why BSA must be accurately calculated before any cardiac imaging interpretation — the threshold for intervention is BSA-dependent.

Average BSA reference values by age: Newborn: ~0.25 m². 1 year: ~0.44 m². 2 years: ~0.50 m². 5 years: ~0.73 m². 8 years: ~0.90 m². 10 years: ~1.14 m². 12 years: ~1.30 m². 14 years: ~1.50 m² (female) / ~1.60 m² (male). Adult range: reached ~15–17 years. These values are critical references for paediatric drug dosing, chemotherapy, fluid management, and nutritional support. The Haycock formula is the most validated across the full paediatric age range. Paediatric BSA should be recalculated at every clinical encounter because children are growing continuously.

Children are not small adults — their organ maturation, metabolic enzyme activity (CYP450 isoforms), and drug distribution volumes change dramatically from birth to adolescence. Weight-based dosing alone (mg/kg) is used for most paediatric medications, but for narrow therapeutic index drugs like chemotherapy, BSA-based dosing better accounts for the allometric relationship between body size and metabolic capacity. A 10-year-old child receiving carboplatin, doxorubicin, or vincristine will have their dose calculated per m² BSA using the Haycock formula — with the dose recalculated at each cycle. Dosing errors in paediatric oncology are among the most dangerous medication errors in hospital practice, which is why standardised BSA calculation protocols are mandatory.

Not recommended. Adult-derived BSA formulas (particularly Du Bois and Gehan-George) were validated primarily in adults and become less accurate in children — especially infants and toddlers with proportionally larger heads and shorter limbs. The Haycock formula was specifically derived and validated across the full paediatric and adult size range and is the recommended equation for all patients from neonates to adults in paediatric clinical pharmacy references. The Mosteller formula is also acceptable in school-age children and adolescents but less precise in infants. The calculator on this page is designed for adults aged 18+; always use paediatric-validated equations and specialist paediatric clinical pharmacy support for children.

% TBSA burned is the percentage of the body’s total surface area affected by burns — the single most important variable in burn assessment. It determines: (1) whether a patient requires hospital admission (typically >10% TBSA); (2) resuscitation fluid volumes; (3) nutritional requirements; (4) prognosis. Estimation methods: The Rule of Nines divides the adult body into 9% segments (each arm 9%, each leg 18%, anterior trunk 18%, posterior trunk 18%, head 9%, perineum 1%). The Lund and Browder chart is more accurate and age-adjusted (used for children). The Rule of Nines is imprecise in obesity or children — the palm of the hand (including fingers) = ~1% TBSA for quick estimation of scattered burns.

The Parkland Formula for burn fluid resuscitation: Total IV fluid (mL) in first 24 hours = 4 mL × Body weight (kg) × % TBSA burned. Half is given in the first 8 hours; half in the next 16 hours. The formula uses body weight (not full BSA) but % TBSA burned is the critical variable derived from BSA assessment. Under-resuscitation causes hypovolaemic shock, AKI, and multi-organ failure. Over-resuscitation causes pulmonary oedema, abdominal compartment syndrome, and worsened burns depth. A 1% error in %TBSA estimation in a large burn patient (70 kg, 40% TBSA) produces a 280 mL difference in fluid volumes — clinically significant. Accurate burn %TBSA assessment is therefore as critical as any laboratory test.

BSA increases with both weight and height. Athletes and bodybuilders carry significantly more skeletal muscle than the general population — muscle has greater volume and mass per unit than adipose tissue, directly increasing body surface dimensions. A 108 kg competitive bodybuilder at 183 cm may have a BSA of 2.30–2.40 m² vs an average male BSA of 1.90 m². This directly impacts: (1) eGFR interpretation — their reported eGFR underestimates true kidney function (see eGFR section); (2) Drug dosing — any BSA-based medication dose will be higher than average; (3) Heat management — lower BSA/mass ratio increases heat illness risk during intense training. Athletes should know their BSA and share it with any treating clinician for accurate drug dose calculations.

BSA/mass ratio (m²/kg) measures heat dissipation efficiency per kg of body mass. Higher ratio (lean, lighter athletes — marathon runners, cyclists) = more efficient heat loss per kg = thermoregulatory advantage in warm-weather endurance events. Elite marathoners typically have ratios of 0.028–0.032 m²/kg. Lower ratio (heavy power athletes — powerlifters, rugby props, heavyweight combat sports) = less efficient heat loss = significantly elevated risk of exertional heat illness. Powerlifters may have ratios as low as 0.018–0.022 m²/kg. Sports science research (Topend Sports, 2025) confirms athletes with BSA/mass below 0.022 m²/kg should implement structured cooling protocols, pre-cooling strategies, and increased hydration targets (add 200–300 mL/hour for every 0.2 m² above 1.8 m² BSA) during training in ambient temperatures above 25°C.

Athletes should recalculate BSA: (1) Quarterly — or at the start and end of each training macro-cycle; (2) Whenever body weight changes by ≥5 kg (e.g., post-bulk, post-cut, weight-class changes); (3) Before any medical procedure or drug treatment that uses BSA-based dosing — always provide your current height and weight to your clinician; (4) After significant body recomposition (e.g., 10%+ body fat change). A 5 kg weight change from 90 to 95 kg at 183 cm changes Mosteller BSA from approximately 2.13 to 2.19 m² — a 2.8% change. For BSA-based chemotherapy dosing, even a 2–3% BSA difference can produce a clinically meaningful dose change in narrow therapeutic index drugs.

BSA is one of several factors in heat illness risk stratification. Athletes with BSA >2.0 m² and low BSA/mass ratio have approximately 30% higher risk of heat illness in hot conditions (Topend Sports, 2025). However, acclimatisation status, fitness level, hydration, clothing, and ambient humidity are equally or more important. The complete heat risk picture combines: BSA/mass ratio (thermoregulatory efficiency), VO₂ max (aerobic fitness reduces heat strain), acclimatisation status (10–14 days of heat exposure reduces core temperature by 0.5–1°C at matched work rate), sweat rate and sodium loss (high BSA athletes lose more fluid volume per hour), and environmental heat stress (WBGT index). BSA alone is not sufficient to predict heat stroke — but it provides the physiological foundation for personalised heat management planning.

In obesity, the additional weight is predominantly adipose tissue — which is metabolically far less active per kg than lean muscle. BSA increases because body dimensions (surface area) increase with weight, regardless of tissue type. However, hepatic drug clearance, renal clearance, and other pharmacokinetic parameters scale primarily with lean body mass, not total BSA. This means an obese patient with BSA 2.50 m² does not have the same metabolic drug clearance capacity as an athletic individual with BSA 2.50 m². For chemotherapy dosing in obesity, using actual weight BSA risks overdosing relative to metabolic clearance capacity — which is why ASCO guidelines, while recommending actual weight dosing, also specify that oncology pharmacists must review doses at BSA extremes (>2.2 m²) and monitor for toxicity closely.

Ideal body weight (IBW) BSA is calculated by substituting ideal body weight (IBW = 50 kg + 2.3 kg per inch over 5 feet for males; 45.5 kg + 2.3 kg per inch over 5 feet for females) into the BSA formula instead of actual weight. It is used for: (1) Cockcroft-Gault creatinine clearance calculation in obese patients — using actual weight produces an overestimate of renal drug clearance; (2) Selected chemotherapy protocols that specify lean body weight or IBW in morbidly obese patients; (3) Drug dosing decisions where adipose tissue distribution of the drug is negligible (hydrophilic drugs). For lipophilic drugs that distribute into fat tissue (e.g., some anaesthetic agents), actual weight or adjusted body weight (ABW = IBW + 0.4 × [actual weight – IBW]) is more appropriate.

BSA correlates more strongly with basal metabolic rate (BMR) than raw body weight in lean individuals, because metabolic organs (liver, kidneys, heart, brain) scale with lean body mass — which in turn scales with BSA. The Dubois and Harris-Benedict BMR equations historically incorporated BSA-derived concepts. In clinical nutrition, BSA-based energy requirements are used for patients with large burns where energy loss through the burned skin surface must be estimated: the Curreri formula estimates caloric needs as 25 kcal × kg + 40 kcal × % TBSA burned. For healthy athletes, BSA alone does not directly calculate caloric needs — BMR then multiplied by an activity factor (Harris-Benedict or Mifflin-St Jeor) remains the standard approach. However, athletes with BSA >2.0 m² have proportionally higher BMR and energy needs than a 1.73 m² reference individual.

Yes, but BSA changes proportionally less than weight because BSA scales with weight raised to a fractional power (~0.425–0.51 depending on the formula). Example using Mosteller: A male at 183 cm — weight 110 kg gives BSA 2.36 m²; weight 85 kg (25 kg loss) gives BSA 2.08 m² — a 12% reduction despite a 23% weight reduction. This sublinear relationship is clinically important in oncology — cancer patients losing significant weight during chemotherapy may have their BSA recalculated each cycle to avoid overdosing on a shrinking body. For athletes, cutting 10 kg for a weight class competition changes BSA by approximately 5–6% — potentially relevant for any BSA-based drug calculation during the competitive period.

BSA measures the external surface area of the body — a physical dimension. Body composition analysis (DEXA, BIA, hydrostatic weighing) measures the internal composition — the proportions of lean mass, fat mass, bone mass, and water. They provide completely different information: BSA is used for drug dosing, cardiac index, eGFR normalisation, and thermoregulation modelling. Body composition analysis is used for health risk stratification, athletic performance optimisation, and nutritional planning. Two individuals can have identical BSA but completely different body compositions (one lean athlete, one obese individual) — which is why BSA alone is insufficient for clinical decisions that depend on metabolic function or cardiovascular risk.

BSA alone is a poor predictor of body fat percentage — it measures total surface area regardless of body composition. However, BSA relative to weight (BSA/weight ratio) provides a crude indicator: a low BSA/weight ratio (small surface area per kg of body mass) suggests a higher proportion of body mass is internal adipose tissue rather than external lean mass. Some research models have incorporated BSA alongside other measurements (waist circumference, skinfold measurements) as part of multi-variable body composition estimates. For accurate body fat percentage measurement, DEXA (gold standard), air displacement plethysmography (Bod Pod), or validated multi-site skinfold calipers provide far more meaningful data than BSA-derived estimates.

Three key things to share: (1) Your actual current height and weight — so your doctor can calculate your true BSA for any drug dosing decisions. Do not assume your doctor has this information or that it is stored accurately in your records. (2) Your training status — if you are an athlete or bodybuilder, this is essential context for interpreting any borderline kidney function (eGFR) results. Elevated creatinine from muscle mass + elevated BSA can both lead to underestimated eGFR. A cystatin-C eGFR test is more accurate in this situation. (3) Any supplements — particularly creatine, which increases serum creatinine independently of BSA effects. Together, these three pieces of information allow your clinician to accurately interpret kidney function results and calculate appropriate drug doses for your actual body size.

No — BSA is a physical measurement, not a health metric with an optimal target value. A higher or lower BSA is not intrinsically better or worse for health. What matters is the reason for your BSA. High BSA due to lean muscle mass in a trained athlete is associated with excellent cardiovascular and metabolic health. High BSA due to morbid obesity is associated with increased cardiometabolic disease risk — but this is because of the adipose tissue and its metabolic consequences, not the BSA number itself. Low BSA due to naturally lean, fit physique is healthy. Low BSA due to cachexia or malnutrition is a serious clinical concern. The health meaning of your BSA must always be interpreted in the context of your body composition, lifestyle, and clinical picture.

Different online calculators use different BSA equations — Mosteller, Du Bois, Haycock, Gehan-George, or Fujimoto. At normal BMI, differences between them are typically less than ±5% and not clinically significant for general fitness purposes. Larger differences arise when: (1) the calculator uses a different primary formula than you expect; (2) unit conversion errors (lbs vs kg, inches vs cm) — always verify your inputs; (3) the calculator rounds intermediate values before taking the final square root or power calculation, which can introduce small but cumulative rounding errors. For clinical purposes (chemotherapy dosing, cardiac index), always confirm which formula your clinical protocol specifies and use the Genghis Fitness BSA calculator’s formula selector to match your clinical protocol exactly.